Home › Diffuse Large B-Cell Lymphoma › Texas › Houston
Pag-aaral pangklinika para sa Diffuse Large B-Cell Lymphoma sa Houston, TX
Isang pag-aaral para sa Diffuse Large B-Cell Lymphoma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Houston. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Nagre-recruitPhase 1/2
- Md Anderson Cancer Center, Houston
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Nagre-recruitPhase 3
- Houston Methodist Cancer Center ( Site 0154), Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Nagre-recruitPhase 1
- Baylor College of Medicine, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Nagre-recruitPhase 1
- MD Anderson Cancer Center, Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Nagre-recruitPhase 1/2
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Nagre-recruitPhase 1
- Md Anderson Cancer Center, Houston
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Nagre-recruitPhase 2
- MD Anderson Cancer Center, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Nagre-recruitPhase 1/2
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Nagre-recruitPhase 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Nagre-recruitPhase 3
- MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Nagre-recruitPhase 1
- The University of TX MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
Nagre-recruitPhase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nagre-recruitPhase 1
- MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Nagre-recruitObservasyonal na pag-aaral
- Texas Children's Hospital, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nagre-recruitPhase 1
- MD Anderson Cancer Center, Houston
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Nagre-recruitPhase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
Nagre-recruitPhase 1
- MD Anderson Cancer Center, Houston
Pag-aaral para sa Diffuse Large B-Cell Lymphoma sa ibang lungsod
- New York City, NY21 pag-aaral
- Baldwin Park, CA19 pag-aaral
- Chicago, IL18 pag-aaral
- Los Angeles, CA17 pag-aaral
- Milwaukee, WI16 pag-aaral
- Boston, MA16 pag-aaral
- Philadelphia, PA15 pag-aaral
- Portland, OR15 pag-aaral
- Durham, NC14 pag-aaral
- Nashville, TN14 pag-aaral
- Dallas, TX13 pag-aaral
- Seattle, WA12 pag-aaral
Iba pang pag-aaral sa Houston
- Non-Small Cell Lung Cancer145 pag-aaral
- Kanser sa Suso126 pag-aaral
- Kanser (lahat ng uri)123 pag-aaral
- Metastatic Cancer104 pag-aaral
- Colorectal Cancer102 pag-aaral
- Kanser sa Ovary89 pag-aaral
- Acute Myeloid Leukemia86 pag-aaral
- Kanser sa Baga78 pag-aaral
- Kanser sa Prostate76 pag-aaral
- Kanser ng Endometrium68 pag-aaral
- Kanser sa Pancreas62 pag-aaral
- Melanoma59 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.